Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

If approved, sibeprenlimab could provide patients with the first disease-modifying therapy that addresses both the clinical ...

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different ...